Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Improvements in Clinical Global Impression of Change (CGIC) with Deutetrabenazine Treatment in Moderate to Severe Tardive Dyskinesia (TD) (S56.004)

Conclusions:Deutetrabenazine 24 and 36 mg/day led to clinically significant reductions in abnormal involuntary movements in patients with TD based on AIMS and CGIC results. The high correlation between AIMS ratings and CGIC demonstrates that treating clinicians could recognize reduced severity of movements, making results applicable to clinical practice.Study Supported by:This study was funded by Teva Branded Pharmaceutical Products R&D, Inc. Petach Tikva, IsraelDisclosure: Dr. Fernandez has received personal compensation for activities with Prime Education Inc, Carling Communications, Medscape, Biogen, GE Health Care, Lundbeck, Merz Pharmaceuticals and Pfizer Pharmaceuticals. Dr. Fernandez has received personal compensation for activities in an editorial capacity for the MDS Web Site. Dr. Fernandez has received royalty payments from Demos Publishing. Dr. Fernandez has received research support from Abbvie, Acadia, Auspex/Teva, Biotie/Acorda Therapeutics, Civitas, Kyowa/Prostrakan, Michael J. Fox Foundation, Movement Disorders Society, NIH/NINDS, Parkinson Study Group, Rhythm, Synosia, and Teva. Dr. Hauser has received personal compensation for activities with Guidepoint Global, SAI-Mmed Partners, Scienomics Group, Gerson Lehrman Group, LCN Consulting, Putnam Associates, National Parkinson Foundation, eResearch Technology, Inc., Lundbeck LLC, Krog & Partners, and Cynapsus as a consultant. Dr. Hauser has received licensing fee payments from the University of South Flor...

Source: Neurology - April 17, 2017 Category: Neurology Authors: Fernandez, H. H., Hauser, R. A., Davis, M. D., Factor, S. A., Isojarvi, J., Jimenez-Shahed, J., Ondo, W. G., Stamler, D., Anderson, K. E. Tags: Movement Disorders: Huntington ' s Disease and Drug-Induced Dyskinesias Source Type: research